Rectal NETs and rectosigmoid junction NETs may need to be treated differently

Neuroendocrine tumors (NETs) are heterogeneous, and the incidence of NETs is rapidly increasing. We observed different survival in patients with rectal NETs and rectosigmoid junction NETs, which are treated similarly. We included patients with rectal and rectosigmoid junction NETs from the SEER data...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2020-02, Vol.9 (3), p.971-979
Main Authors: Cai, Wen, Ge, Weiting, Hu, Hanguang, Mao, Jianshan
Format: Article
Language:English
Subjects:
Adult
Aged
Chemoradiotherapy, Adjuvant - standards
Clinical Cancer Research
Clinical medicine
Colectomy - standards
Colon, Sigmoid - pathology
Colon, Sigmoid - surgery
Epidemiology
Female
Humans
Kaplan-Meier Estimate
Lymph Nodes
Lymphatic Metastasis - diagnosis
Lymphatic Metastasis - therapy
Lymphatic system
Male
Medical prognosis
Metastases
Metastasis
Middle Aged
Neoadjuvant Therapy - methods
Neoadjuvant Therapy - standards
Neoplasm Invasiveness
Neoplasm Staging
Neuroendocrine tumors
Neuroendocrine Tumors - diagnosis
Neuroendocrine Tumors - mortality
Neuroendocrine Tumors - pathology
Neuroendocrine Tumors - therapy
Original Research
Patients
Practice Guidelines as Topic
Proctectomy - standards
Rectal Neoplasms - diagnosis
Rectal Neoplasms - mortality
Rectal Neoplasms - pathology
Rectal Neoplasms - therapy
rectosigmoid junction
Rectum
Rectum - pathology
Rectum - surgery
Risk Assessment - statistics & numerical data
Risk Factors
SEER Program - statistics & numerical data
Sex Factors
Sigmoid Neoplasms - diagnosis
Sigmoid Neoplasms - mortality
Sigmoid Neoplasms - pathology
Sigmoid Neoplasms - therapy
Surgery
Surveillance
Survival
Survival analysis
Survival Rate
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neuroendocrine tumors (NETs) are heterogeneous, and the incidence of NETs is rapidly increasing. We observed different survival in patients with rectal NETs and rectosigmoid junction NETs, which are treated similarly. We included patients with rectal and rectosigmoid junction NETs from the SEER database. The 5‐year survival was set as the end‐point. 6675 patients with rectal NETs and 329 patients with rectosigmoid junction NETs, were eligible for the analysis. Initially, the survival analyses suggested that the 5‐year survival significantly differed between the patients with rectal and rectosigmoid junction NETs (HR = 0.82, 95% CI 0.70‐0.95; P = .01). Tumor differentiation, an invasion deeper than T2, and lymph node and distant metastases were still important risk factors affecting survival for both location. While, the males showed better survival (HR = 0.69, 95% CI 0.55‐0.88; P  5, P  5, P 
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.2779